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AbstrACt
Cases of the 2019 novel coronavirus also known as severe 
acute respiratory syndrome coronavirus 2 (SARS- CoV-2) 
continue to rise worldwide. To date, there is no effective 
treatment. Clinical management is largely symptomatic, 
with organ support in intensive care for critically ill 
patients. The first phase I trial to test the efficacy of a 
vaccine has recently begun, but in the meantime there is 
an urgent need to decrease the morbidity and mortality 
of severe cases. It is known that patients with cancer are 
more susceptible to infection than individuals without 
cancer because of their systemic immunosuppressive 
state caused by the malignancy and anticancer treatments. 
Therefore, these patients might be at increased risk of 
pulmonary complications from COVID-19. The SARS- 
CoV-2 could in some case induce excessive and aberrant 
non- effective host immune responses that are associated 
with potentially fatal severe lung injury and patients can 
develop acute respiratory distress syndrome (ARDS). 
Cytokine release syndrome and viral ARDS result from 
uncontrolled severe acute inflammation. Acute lung injury 
results from inflammatory monocyte and macrophage 
activation in the pulmonary luminal epithelium which 
lead to a release of proinflammatory cytokines including 
interleukin (IL)-6, IL-1 and tumor necrosis factor-α. 
These cytokines play a crucial role in immune- related 
pneumonitis, and could represent a promising target 
when the infiltration is T cell predominant or there are 
indirect signs of high IL-6- related inflammation, such 
as elevated C- reactive protein. A monoclonal anti- IL-6 
receptor antibody, tocilizumab has been administered in 
a number of cases in China and Italy. Positive clinical and 
radiological outcomes have been reported. These early 
findings have led to an ongoing randomized controlled 
clinical trial in China and Italy. While data from those trials 
are eagerly awaited, patients’ management will continue 
to rely for the vast majority on local guidelines. Among 
many other aspects, this crisis has proven that different 
specialists must join forces to deliver the best possible 
care to patients.
New cases of the 2019 novel coronavirus also 
known as severe acute respiratory syndrome 
coronavirus 2 (SARS- CoV-2) continue to 
rise worldwide. On March 11th, 2020, the 
WHO declared a pandemic, with 118,326 
confirmed cases and 4292 deaths reported1 
with a mortality rate of 3.6%2 whereas the 
mortality for critical cases can reach 60.5%.3 
To date, there is no effective treatment. 
Clinical management is largely symptomatic, 
with organ support in intensive care for crit-
ically ill patients. The unprecedented flurry 
of activity by the WHO and other global 
public health bodies has mainly focused on 
preventing transmission, through infection 
control measures, including screening of 
travelers. The development of vaccines has 
received immediate support and the first 
phase I trial has just begun (NCT04283461). 
However, there is an urgent need to focus 
funding and scientific investments into 
advancing novel therapeutic interventions 
for coronavirus infections, to decrease the 
morbidity and mortality of severe cases. The 
results of the first randomized trial assessing 
antivirals (lopinavir and ritonavir) failed to 
show any clinical benefit.4
The China International Exchange and 
Promotive Association for Medical and 
Healthcare (CPAM)5 has issued guidelines 
about the potential treatment of coronavirus 
virus disease 2019 (COVID-19) which include 
antiviral and immune- modulating drugs such 
as chloroquine. Nevertheless none of them 
has proven to be effective thus far and combi-
nation trials are ongoing (NCT04319900).
It is known that patients with cancer are 
more susceptible to infection than individ-
uals without cancer because of their systemic 
immunosuppressive state caused by the malig-
nancy and anticancer treatments. Therefore, 
these patients, and in particular lung cancer 
patients, might be at increased risk of pulmo-
nary complications from COVID-19.
risk of CoViD-19 in CAnCer pAtients
Severe COVID-19 can be considered a hyper-
inflammatory disorder characterized by 
massive immune cell activation. As such, this 
may explain worse outcomes in older people 
and cancer patients. While it could be hypoth-
esized that the lowered immunity induced 
by cancer itself or its treatment could be a 
protective element against the major immune 
reaction seen in COVID-19, there is a biolog-
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increase in inflammation is common during aging and 
has been defined ‘inflamm- aging’.6 Chronic inflamma-
tion, including from cancer and age, as well as immune 
checkpoint inhibitors (ICIs) can cause a surge in proin-
flammatory immune responses, leading to enhanced 
production of cytokines from T cells and phagocytes. 
In lung cancer in particular, there is chronic pulmo-
nary inflammation, both from the tumor microenviron-
ment and the frequent underlying lung pathology.7 This 
immune deregulation observed in older, lung cancer, or 
ICI- treated patients may drive the severe pathogenesis of 
COVID-19 in these special populations.
Additionally, T cells produce proinflammatory cyto-
kines with multiple functions, such as recruiting mono-
cytes and neutrophils to the site of infection and activating 
other downstream cytokine and chemokine cascades.8–10
Recently Liang et al11 showed an over- representation of 
cancer patients in the COVID-19 cohort. Therein, lung 
cancer was the most frequent type (5 (28%) of 18 patients). 
Based on their results, the authors have proposed three 
major strategies for patients with cancer in this COVID-19 
crisis: (1) To postpone all adjuvant systemic therapy or 
elective surgery for stable cancer in endemic areas. (2) 
To increase personal protection provisions for patients 
with cancer and at- risk cancer survivors. (3) To intensify 
surveillance in cancer patients infected with SARS- CoV-2. 
Although these recommendations came from a small 
sample size with a large amount of heterogeneity, there is 
an increasing consensus to modify our standard manage-
ment during this pandemic. Patients with lung cancer 
are prone to severe complications, such as admission to 
the intensive care unit requiring invasive ventilation, or 
death, from COVID-19. Smoking has also been identified 
as an independent risk factor in severe COVID-19 cases.12
Yu et al13 published a retrospective analysis about 1524 
patients with cancer who were admitted to the Depart-
ment of Radiation and Medical Oncology, Zhongnan 
Hospital of Wuhan University. They reported the 
outcomes of COVID-19 among those patients. The 
study highlighted that patients with cancer harbored a 
higher risk of SARS- CoV-2 infection (OR, 2.31; 95% CI, 
1.89 to 3.02) compared to the general population. This 
risk appears increased in both patients with or without 
active anticancer treatments. The most likely to develop 
COVID-19 were patients with non- small cell lung cancer 
(NSCLC) and above the age of 60.
Furthermore, the Lung Cancer Study Group, Chinese 
Thoracic Society, Chinese Medical Association and the 
Chinese Respiratory Oncology Collaboration have issued 
recommendations about the management of patients 
with advanced NSCLC during the COVID-19 epidemic.14 
(1) Whenever possible, patients with advanced NSCLC 
should be treated as outpatients at the nearest medical 
center. (2) Patients who need to be hospitalized for 
antitumor treatment should be tested beforehand for 
COVID-19 infection. (3) Close attention should be paid 
to identification of COVID-19- related symptoms and 
adverse reactions caused by the malignancy or antitumor 
treatments. (4) Stringent personal protection protocols 
should be applied to advanced NSCLC patients. (5) An 
intentional postponing of antitumor treatment should 
be considered according to patient performance status. 
(6) Treatment strategies should be tailored to the type of 
NSCLC, the patient, and efficacy and expected toxicity 
of each drug. Recently Ruan et al showed that, among 
patients who died from COVID-19, 63% had underlying 
disease, whereas 41% of those discharged did.15 An early 
report of a subset of patients who died from COVID-19 
in Italy found that 20.3% of the deceased had active 
cancer.16 All of this underlines the increased risk for 
cancer patients, particularly lung cancer patients.
immunopAthophysiology of sArs-CoV-2 lung injury
Biopsies, lobectomies and autopsies have yielded data 
about the histologic reflection of the pathophysiology of 
COVID-19. A particularly interesting report concerns two 
patients with lung cancer treated with lobectomy, retro-
spectively diagnosed with COVID-19, offering a glimpse 
into the early pathologic presentation of this disease.17 
As in the original SARS disease, COVID-19 can induce 
exudative as well as proliferative lung injury in the acute 
setting. Today, we know that the main histological find-
ings in COVID-19 lung lesions are typical signs of alveolar 
damage, including the triad of injury to alveolar epithe-
lial cells, type II pneumocyte hyperplasia and hyaline 
membrane formation.18 The hallmark hyaline membrane 
formation seen in SARS and observed in subsequent 
pathologic analyzes of COVID-19 were lacking, shedding 
light on the chronology acute lung injury. In this case, 
this constellation was likely because these patients were 
operated at a presymptomatic stage. A notable observa-
tion was an abundant infiltration of alveolar macrophages 
and mononuclear inflammatory cells. Interestingly, the 
authors point out that while clinically asymptomatic, 
these patients did present leukocytosis with lymphopenia, 
suggesting the immune response was underway at this 
early disease stage.17 Similarly, radiographic changes can 
precede symptoms and must be interpreted cautiously 
during an epidemic.
The pathophysiology of the COVID-19 is not yet 
completely elucidated. However, in some cases, the 
SARS- CoV-2 induces excessive and aberrant non- effective 
host immune responses that are associated with poten-
tially fatal severe lung injury.19 The novel coronavirus 
might mainly act on lymphocytes, especially T lympho-
cytes.19 Patients can develop acute respiratory distress 
syndrome (ARDS) with characteristic pulmonary ground 
glass changes on imaging (figure 1). In some severe cases, 
this infection can be associated with a cytokine storm and 
macrophage activation syndrome (MAS), characterized 
by increased plasma concentrations of interleukin (IL)-2, 
IL-7, and IL-10, granulocyte- colony stimulating factor, 
interferon-γ-inducible protein, monocyte chemoattrac-
tant protein, macrophage inflammatory protein and 
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Figure 1 Chest CT showing typical ground glass opacities 
in acute respiratory distress syndrome, in this case in a lung 
cancer patient with COVID-19.
of MAS is the over- activation of tissue macrophages for 
the release of a storm of cytokines leading to rapidly 
progressing organ dysfunction where pancytopenia, 
tissue hemophagocytosis, hepatobiliary dysfunction, 
disseminated intravascular coagulation, and dysfunction 
of the central nervous system predominate. MAS can be 
fatal. The hallmark of pathogenesis is the overproduction 
of IL-1β by tissues macrophages. IL-1β acts through auto-
crine stimulation of macrophages leading to a vicious cycle 
of further cytokine production and exaggerated inflam-
mation. Moreover, IL-1 signaling drives the acute phase 
response to infection,21 the Th17 differentiation22 and 
the immunopathogenic response observed in in ARDS 
and acute lung injury.23 Interestingly, a proinflammatory 
Th17 signature has been reported in patients infected 
with SARS- CoV-224 and with MERS- CoV.25 Elevated serum 
of interferon (IFN)-γ has been recently reported in 
patients with ARDS in COVID-19.26 27 Additionally, IFN-γ 
is pleiotropic cytokine and enhances IL-6 production in 
monocytes28 (figure 2). IFN- γ exerts its pleiotropic effects 
through the Janus kinase (JAK)1/JAK2 signaling leading 
to the activation of a large downstream cascade.29 Histor-
ically, IFN-γ has been implicated in the pathogenesis of 
‘cytokine storm’ in various autoimmune diseases and also 
in hemophagocytic lymphohistiocytosis.23
In a small fraction of septic patients, proinflammatory 
phenomena predominate and a more specific treatment 
might be associated with better outcomes.30
IL-6 blockade is frequently administered to patients with 
cancer in the context of immune checkpoint- inhibitor- 
induced immune- related adverse events, particularly in 
steroid resistant ones,31 as well as to dampen cytokine- 
release syndrome which can complicate chimeric antigen 
receptor T cell (CAR- T) therapy.32 ICI- related pneumo-
nitis and SARS- CoV-2 induced ARDS have overlapping 
features, sharing a clinical and radiological presentation. 
ICI- induced pneumonitis, cytokine release syndrome 
and viral ARDS result from uncontrolled severe acute 
inflammation. Acute lung injury results from inflam-
matory monocyte and macrophage activation in the 
pulmonary luminal epithelium which lead to a release 
of proinflammatory cytokines including IL-6, IL-1 and 
TNF-α.33
In addition to acute inflammation, IL-6 stimulates 
T cell proliferation and it has a critical role: it exerts a 
negative impact on the ability of pulmonary dendritic 
cells to prime naive T cells, thus downplaying the adap-
tive immune response.33 Corticosteroids are standard 
frontline therapy for ICI- induced pneumonitis34 and 
they have been tested in SARS- CoV-2 induced ARDS in 
order to suppress the cytokine storm. Their use remains 
controversial as they do not prolong survival.35 36 IL-1 
blockade has been assessed data from a phase III random-
ized controlled trial of the anti- IL-1 monoclonal anti-
body, anakinra, in septic patients with features of MAS, 
showed significant survival benefit, without increased 
adverse events.37 Ongoing trials of cellular therapies for 
treatment of ARDS could be expanded to treatment of 
critically ill patients with SARS- CoV-2 infection. Cellular 
therapy using mesenchymal stromal cells from allogeneic 
donors is being evaluated in patients with ARDS, as it 
reduces non- productive inflammation and affects tissue 
regeneration (NCT02804945; NCT03608592).
future therApeutiC DireCtions
While the pathophysiology is multifaceted, IL-6 seems to 
play an important role in immune- related pneumonitis, 
and could represent a possible target if there are indirect 
signs of high IL-6- related inflammation, such as elevated 
C- reactive protein. Among cancer patients who developed 
ICI- induced pneumonitis with signs of high inflammation 
in blood tests, 79.4% responded well to the monoclonal 
anti- IL-6 receptor antibody, tocilizumab (TCZ) within 7 
days.38 It has been administered in a number of cases in 
China and Italy. As recently published in a statement from 
the Society for Immunotherapy of Cancer (SITC) on 
IL-6 therapies for COVID-19, the authors reported rapid 
improved clinical, biological and radiological outcomes, 
as soon as 5 days after TCZ treatment. This has led to 
compassionate use of TCZ in several countries and the 
SITC statement recommends all efforts be made to allow 
for emergency approval of this drug.39 Furthermore, a 
single center experience reported that TCZ appears to 
be an effective treatment option in COVID‐19 patients 
with a risk of cytokine storm. However the result should 
be evaluated with caution given the combination with 
methylprednisolone and the small number of cases and 
the treatment duration.
Controlled clinical trial are ongoing in China and 
Italy aiming to confirm the safety and efficacy of TCZ in 
COVID-19 (ChiCTR2000029765 and TOCIVID-19) and 
the Food and Drug Administration (FDA) has approved 
a phase III, placebo- controlled, randomized clinical trial 
of TCZ (COVACTA).
The hypercytokinemia in COVID-19 may be addressed 
as a result and driver of immune cell activation. The over- 
activation of T cells and macrophages excessively produce 
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Figure 2 Autocrine macrophage activation. The hallmark of pathogenesis of macrophage activation syndrome, as can be seen 
in COVID-19, is the overproduction of IL-1β by tissues macrophages. IL-1β, as well as other proinflammatory cytokines, acts 
through autocrine stimulation on macrophages leading to a vicious cycle of cytokine production and hyperinflammation. gp130, 
glycoprotein 130; IFN, interferon; IL, interleukin; R, receptor; TLR, toll- like receptor; TNF, tumor necrosis factor.
One important pathophysiological mechanism is that 
macrophages use the Janus kinase- signal transducer and 
activator of transcription proteins (JAK- STAT) system.40
Other immune- modulating therapies are potential 
candidates. Agents able to alleviate activation of JAK1/
JAK2 using ruxolitinib, of IL-6/IL- 6R signaling (using 
TCZ or an anti- IL-6 antibody such as siltuximab), of IL-1 
signaling (using anakinra which is a recombinant human 
IL- 1R antagonist or using canakinumab that is a human 
monoclonal anti- IL-1β antibody) or anti- IFN-γ (using 
emapalumab that is a human anti- IFN-γ monoclonal anti-
body) are promising therapeutic strategies to treat the 
hypercytokinemia syndrome associated with severe forms 
of COVID-19 (figure 3).
Several non- immune- modulating therapies are being 
been explored. Chloroquine and hydroxychloroquine 
are antimalarial drugs which have shown antiviral effects 
against many types of viruses, in vitro, including in HIV. 
They rely on two identified mechanisms of action: inhib-
iting low pH- dependent viral entry into host cells and 
altering post- translational modifications of newly synthe-
sized proteins by blocking glycosylation.41
Combining chloroquine with the antiviral, remdesivir, 
inhibits the growth of SARS- CoV-2 in vitro42 and early 
trials in China suggest a beneficial effect of chloroquine 
in terms of biological (viral load) and clinical outcomes.43 
While trials are ongoing, consensus guidelines recom-
mend its use in China.14
Hydroxychloroquine, which has a more favorable toxicity 
profile than chloroquine, has been shown to be more 
potent than chloroquine to inhibit SARS- CoV-2 in vitro.44 
The former’s potential role is corroborated by its efficacy in 
clearing nasopharyngeal carriage of SARS- CoV-2, reducing 
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Figure 3 Acute inflammation in COVID-19 and treatment strategies. In response to the viral infection, inflammatory monocyte 
and macrophage activation in the pulmonary luminal epithelium leads to a massive release of proinflammatory cytokines 
including IL-6, IL-1 and TNF-α (the different treatment strategy should be highlighted). These are potential targets currently 
under investigation. DAMPS, damage- associated molecular patterns; gp130, glycoprotein 130; IFN, interferon;IL, interleukin; 
JAK, Janus kinase; R, receptor; sIL- 6R, soluble IL-6 receptor;TNF, tumor necrosis factor.
Furthermore, associating hydroxychloroquine with the 
immunomodulatory macrolide, azithromycin, appears 
to increase the virological cure rate, with 100% of 
patients receiving this combination virus- free after 6 days, 
compared with 57% with hydroxychloroquine alone 
and 12% in the control group without either treatment 
(p<0.001).45 However, no strong evidence supports clin-
ical efficacy of any of these molecules in COVID-19 and 
randomized trials are needed.
Current antiviral studies are ongoing. Remdesivir, a 
nucleotide analog inhibitor of the Ebola virus (EBOV) 
RNA- polymerase RNA- dependent, with promising in vitro 
anti- SARS- CoV-2 efficacy42 and reports from early clinical 
data. The AIDS- approved combination of lopinavir and 
ritonavir had also been adopted as a therapeutic option 
for COVID-19, but a randomized trial of 199 patients 
showed no clinical benefit, reinforcing that early data 
should be interpreted cautiously.4
preVention of CoViD-19 in lung CAnCer pAtients
Today, various recommendations have emerged about 
tailoring cancer therapies, including for NSCLC, to the 
reality of the COVID-19.46 The backbone of all of these 
is to reduce unnecessary exposure, thus reducing the 
risk of transmission. For lung cancer patients, this also 
means carefully weighing the risk- benefit ratio of each 
treatment. While ICI- induced pneumonitis may resemble 
COVID-19, both on a pathophysiological and clinical 
level, there is no evidence suggesting patients receiving 
these treatments are at increased risk of severe COVID-19 
complications, compared with those on other oncological 
therapies. Similarly, no data exist about potential interac-
tion between tyrosine kinase inhibitors and SARS- CoV-2. 
Again, even if drug- induced pneumonitis is suspected, 
COVID-19 should be ruled out. For all NSCLC patients, 
the element to keep in mind; however, is to be reactive. 
While awaiting viral swab confirmation, one should inter-
rupt cytotoxic therapy should biological, clinical or radio-
logical tests be suggestive of COVID-19.
ConClusion
Several unique opportunities to evaluate a range of treat-
ment interventions at the peak of the previous SARS- CoV 
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subsequent decline in cases, leaving numerous questions 
about the coronavirus pathogenesis unanswered. Patients 
with cancer, particularly lung cancer, are at higher risk to 
develop severe complications if infected by SARS- CoV-2, 
hence important measures must be considered to mini-
mize this risk.
As the SARS- CoV-2 continues to spread, and the death- 
toll to rise exponentially, advancing new therapeutic 
development becomes crucial, both to limit the number 
of deaths in general population and patients suffering 
from cancer, and to alleviate the strain on healthcare 
systems worldwide, already struggling to cope with the 
number of victims of this disease.
Thus, the identification of predictive biomarkers asso-
ciated to severe forms of COVID-19 is a ‘conditio sine qua 
non’ to develop personalized care. A better understanding 
of the exact role of immune deregulation in COVID-19 
will facilitate the development and selection of targeted 
treatment while waiting for a vaccine. Targeted immu-
notherapy may represent a valid alternative to antivirals 
which have narrow therapeutic windows and early resis-
tance mechanisms
While we await further data from the countries that 
have been most affected by COVID-19, patient manage-
ment will rely partially on trials, where available, and 
for the vast majority on local guidelines. The TCZ story 
proves that, more than ever, in times of crisis specialists 
from different medical domains can join forces to offer 
the best possible care to patients.
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